Noxopharm Limited (ASX:NOX) confirms a number of key medical appointments as part of the Company’s initiation of its clinical trials program.
Professor Paul de Souza has been appointed as Medical Advisor. Professor de Souza holds the Foundation Chair in Medical Oncology, School of Medicine, Western Sydney University. He formally will advise the Company on both its clinical trial and drug development strategies, plus chair the Company’s Medical Advisory Panel. The position is part-time. Professor de Souza has considerable experience with the Company’s core technologies, having conducted the first Phase 1b clinical study of idronoxil as well as a number of laboratory studies.
Associate Professor Thomas Eade and Associate Professor George Hruby have been appointed as radiation oncology consultants. Both hold senior staff positions at Royal North Shore Hospital, Sydney, and clinical academic positions in the Faculty of Medicine, The University of Sydney.
For further information please download PDF attached:
Download this document
